ArticleBlood advances2018
Increased acute care utilization in a prospective cohort of adults with sickle cell disease.
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Cognitive performance as a predictor of healthcare transition in sickle cell disease.British journal of haematology · 2021Trial
- A Qualitative Phenomenological Study of Treatment Options for Patients with SCD and Chronic Pain: Buprenorphine-Naloxone or Full-Agonist Therapy.International journal of environmental research and public health · 2026Article
- Trends in CT pulmonary angiography utilization and recurrent imaging in sickle cell disease: a longitudinal study.International journal of emergency medicine · 2025Article
- Clinical phenotype of high-impact chronic pain in sickle cell disease at consultation for hematopoietic cell transplant.Journal of sickle cell disease · 2025Article
- Early Administration of Intravenous Hydration and Opioid Analgesics Is Correlated with Decreased Admission Rates during Vaso-Occlusive Episodes in Sickle Cell Disease.Journal of clinical medicine · 2024Article
- Altered pain processing and sensitization in sickle cell disease: a scoping review of quantitative sensory testing findings.Pain medicine (Malden, Mass.) · 2024Article
- Biopsychosocial Factors Associated With Pain and Pain-Related Outcomes in Adults and Children With Sickle Cell Disease: A Multivariable Analysis of the GRNDaD Multicenter Registry.The journal of pain · 2024Article
- Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications.PloS one · 2024Article
- Sex and frequency of pain episodes are associated with acute pain trajectories in adolescents with sickle cell disease.Pain reports · 2023Article
- A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting.Blood advances · 2023Article
- Severe Persistent Pain and Inflammatory Biomarkers in Sickle Cell Disease: An Exploratory Study.Biological research for nursing · 2022Article
- Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.Journal of pain research · 2022Review
- Article
- Emergency Department Utilization for Patients Living With Sickle Cell Disease: Psychosocial Predictors of Health Care Behaviors.Annals of emergency medicine · 2020Article
- Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.Blood advances · 2020Article
- A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease.Current pain and headache reports · 2020Review
- Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program.PloS one · 2020Article
- Development of a Severity Classification System for Sickle Cell Disease.ClinicoEconomics and outcomes research : CEOR · 2020Article
- Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease.PloS one · 2020Article
- Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ESCAPED (Examining Sickle Cell Acute Pain in the Emergency vs Day Hospital) trial is an ongoing prospective study comparing outcomes of people with sickle cell disease (SCD) seeking care for acute pain management in either an emergency department or specialty infusion clinic. The objective of this paper is to describe the baseline characteristics and health care utilization of patients in the trial. This is a multicenter study across 4 US cities that enrolled all adults with SCD living within 60 miles (96.6 km) of a study site who were expected to have acute care utilization over the study period. Twenty-one percent of participants had no acute care visits in the first 12 months of follow-up. Using negative binomial regression, we describe subject characteristics that predict acute care utilization. Three hundred ninety-one subjects have completed 12 months of follow-up with a mean age of 34.5 years (standard deviation, 11.4), 60% are female. Fifty-four percent of subjects with hemoglobin SS disease and 46% with hemoglobin SC disease had 3 or more acute visits over the study period. The prevalence of chronic pain in this cohort was 68%. Predictors of higher rates of acute care utilization included being unemployed, having chronic pain, being on chronic transfusion therapy, having a history of stroke, and being on disability or on Medicaid. This is the first prospective cohort in the modern era, and it demonstrates much higher rates of acute care utilization than reported in the Cooperative Study of Sickle Cell Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.